iCAD to Showcase its Comprehensive Electronic Brachytherapy Solutions and Services at 56th Annual American Society for Therapeutic Radiology and Oncology (ASTRO) Meeting

NASHUA, N.H. and SAN FRANCISCO, Sept. 11, 2014 /PRNewswire/ -- (Booth #1938) -- iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, will debut the Company's latest technological advances and present updates on clinical data and patient outcomes using the Xoft^® Axxent^® Electronic Brachytherapy (eBx^®) System^® in the treatment of cancer during the upcoming American Society for Therapeutic Radiology and Oncology (ASTRO) meeting taking place  September 14-17, 2014 at the Moscone Center in San Francisco. Throughout the meeting, iCAD will also showcase its expanded and comprehensive software and service offerings following the recent acquisitions of DermEbx and Radion, and will highlight innovations in technology with live product demonstrations of its Xoft System at Booth #1938.

"This is a very exciting year for iCAD as we have significantly expanded our position as the industry's leading comprehensive solution provider in eBx. We look forward to outlining the elements of our new solutions and services and to giving customers a hands-on experience with our recent advances to the technology platforms including the debut of our Axxent SPX Controller, the latest extension of the Xoft System product line," said Ken Ferry, President and CEO of iCAD. "With our progress this year, iCAD is uniquely positioned to provide significant technology and service advantages to our valued customers and their patients."

"We continue to be encouraged by the positive data presented on the Xoft System for the treatment of non-melanoma skin cancer, as it further demonstrates the System's distinct clinical and cosmetic advantages," added Mr. Ferry. 

iCAD Technology Updates and Demonstrations

During ASTRO, iCAD will debut the new Axxent SPX Controller, the latest extension of the Axxent product line. The Axxent SPX Controller features a streamlined design to support enhanced mobility and flexibility for delivery of electronic brachytherapy treatment in a wider range of healthcare settings including smaller treatment rooms. The Axxent SPX Controller also features new software and an enhanced bar code scanning function that offers significant workflow benefits and improved technology support for HIPAA compliance. These features are also now available on the multi-platform Axxent MPX Controller, which remains commercially available as the company's platform product approved for use in all indications including breast IORT, breast APBI, skin, endometrial and cervical cancer treatments.

"Electronic brachytherapy allows radiation oncologists to expand the reach of HDR brachytherapy beyond conventional shielded vaults.  It inherently offers safety for patients and personnel, target flexibility for challenging anatomic areas and fine radiation dose control.  The new streamlined design may be easier to integrate into smaller spaces in many clinical facilities," said Rakesh Patel, M.D., Medical Director at The Targeted Radiation Institutes in the East and South Bay Areas, CA. 

Xoft Systems with the Axxent MPX Controller and the Axxent SPX Controller will both be showcased in the Xoft booth (#1938) at the ASTRO meeting. ASTRO attendees are invited to stop by the booth at any time for a personal demonstration of these technologies or for any additional information. Members of iCAD/Xoft management and clinical experts in eBx will also be available at the Xoft booth for briefings or interviews.

For additional information regarding iCAD and the technologies on display at ASTRO 2014, please visit http://www.xoftinc.com/ASTRO.htm or schedule a live demonstration at http://www.xoftinc.com/contact.html.

iCAD Breakfast Symposium

On Tuesday, September 16, 2014, iCAD will host a Breakfast Symposium entitled: "Clinical Advances in Electronic Brachytherapy for Breast, Skin and Gynecological Cancers." This meeting is open to all ASTRO attendees and will be held from 6:45 am to 7:45 am (PT) at the Industry Expert Theater, ASTRO Exhibit Hall, Room 100.

Presenters at the iCAD breakfast meeting include:

• Ajay Bhatnagar, M.D., MBA (Medical Director, 21st Century Oncology of Arizona, Adjunct Assistant Professor of Radiation Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA)
• Parag Sanghvi, M.D. (Assistant Professor, Radiation Oncology, University of California San Diego, San Diego, CA)
• Susan Boylan, M.D. (Medical Director, Potomac Radiation Oncology Center, a joint affiliation of Sentara Healthcare and the Inova Health System, Woodbridge, VA)

iCAD Clinical Data Presentation

On Monday, September 15, 2014, Dr. Bhatnagar will present a poster presentation entitled, "Electronic Brachytherapy for the Treatment of Non-Melanoma Skin Cancer: Results up to 4 Years." The poster (#3386) will be presented from 5:30 pm to 6:30 pm (PT) and will be available for viewing beginning at 10:00 am (PT) on Sunday, September 14, 2014.

iCAD Investor Luncheon

In conjunction with the ASTRO meeting, iCAD is hosting an Investor Luncheon on Monday, September 15, 2014 from noon to 2:00 pm (PT) at the San Francisco Marriott Marquis.  The meeting will feature a clinical discussion with Dr. Rakesh Patel.  For investors interested in attending, please contact Anne Marie Fields, Senior Vice President at LHA, by telephone at (212) 838-377 or by email at [email protected]. 

About Xoft Axxent Electronic Brachytherapy System
The Xoft System is an isotope-free radiation treatment cleared by the U.S. Food and Drug Administration and CE marked in the EU for use anywhere in the body, including for the treatment of early-stage breast cancer, gynecological cancers and non-melanoma skin cancer. It utilizes a proprietary miniaturized x-ray as the radiation source that delivers precise treatment directly to cancerous areas while sparing healthy tissue and organs. The Xoft System requires only minimal shielding and therefore does not require room redesign or construction investment. Minimal shielding also allows medical personnel to remain in the room with the patient during treatment. The mobility of the Xoft System makes it easy to treat patients at multiple locations and to easily store the system when not in use. Xoft is a wholly owned subsidiary of iCAD, Inc. For more information about Xoft visit www.xoftinc.com, like us on Facebook or follow us on Twitter at @xofticad.

About iCAD, Inc.
iCAD delivers innovative cancer detection and radiation therapy solutions and services that enable clinicians to find and treat cancers earlier and faster while improving patient outcomes. iCAD offers a comprehensive range of upgradeable computer aided detection (CAD) and workflow solutions to support rapid and accurate detection of breast, prostate and colorectal cancers. iCAD's Xoft® Axxent® Electronic Brachytherapy (eBx®) System® is a painless, non-invasive technology that delivers high dose rate, low energy radiation, which targets cancer while minimizing exposure to surrounding healthy tissue. The Xoft System is FDA cleared and CE marked for use anywhere in the body, including treatment of non-melanoma skin cancer, early-stage breast cancer and gynecological cancers. The comprehensive iCAD technology platforms include advanced hardware and software as well as management services designed to support cancer detection and radiation therapy treatments. For more information, visit www.icadmed.com or www.xoftinc.com.

For iCAD investor relations, contact Anne Marie Fields of LHA at 212-838-3777 x6604 or via email at [email protected].

For iCAD media inquiries, contact Lynn Granito of Berry & Company Public Relations, LLC at 212-253-8881 or via email at [email protected].

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995
Certain statements contained in this News Release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to the Company's ability to defend itself in litigation matters, to achieve business and strategic objectives, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, uncertainty of future sales levels, protection of patents and other proprietary rights, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence of products, increased competition, litigation and/or government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company's filings with the Securities and Exchange Commission. The words "believe", "demonstrate", "intend", "expect", "estimate", "will", "continue", "anticipate", "likely", "seek", and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC's website at http://www.sec.gov.

SOURCE iCAD, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED